Pharmaceutical crystals have been grown in space for decades of experiments. What's new is that it now works as a business — and here is why it matters.
Most drugs are crystals, and the crystal's form and quality decide how well the drug dissolves, how stable it is, and how consistently it behaves from batch to batch. Over 70% of new drugs dissolve poorly, and for most of them terrestrial formulation science already has answers.
For a stubborn minority it doesn't. The form that works best is metastable — it reverts to a less useful form before it can reach patients — or its quality varies from batch to batch in ways no terrestrial process can eliminate. Those molecules stay stuck: underperforming, delayed, or never launched.
The cause is physical, not chemical. On Earth, gravity drives convection, sedimentation and pressure gradients inside every crystallisation vessel — the hidden sources of crystal defects and variability. Remove gravity, and crystallisation becomes purely diffusion-driven: crystals grow larger, more uniform, and with fewer defects. Fewer defects also means fewer nucleation sites, so a metastable form grown in orbit can hold on far longer — long enough to become a real product.
This is not a hypothesis. Peer-reviewed results and commercial missions have already shown what microgravity does to pharmaceutical crystals.
Varda Space Industries crystallised a metastable form of ritonavir in microgravity and recovered it to Earth — the first commercial drug substance produced in orbit. Six missions have flown since.
Published results from orbital experiments show microgravity-grown crystals that are larger, cleaner and lower-defect than ground controls — and orbital seed crystals that propagate their quality through consecutive terrestrial generations.
Merck, Bristol Myers Squibb, Eli Lilly and AstraZeneca have all run crystallisation or formulation programmes in space — first on the ISS, now increasingly on commercial platforms.
Four things turned in-orbit pharmaceutical manufacturing from a lab curiosity into an investable industry — three of them in just the last three years.
Around twenty commercial re-entry providers are flying or in advanced development, versus zero in 2023. This work no longer depends on the ISS — costly, slow, and approaching retirement.
The cost of reaching low Earth orbit has fallen roughly tenfold over the past decade, driven by reusable rockets and rideshare launches. Getting to orbit is now routine.
Dedicated operators have raised serious private capital and signed collaborations with pharmaceutical companies. Real companies, real missions, real material coming back.
In 2026 the EU saw its first commercial re-entry licence and the UK published its first regulatory roadmap for in-orbit pharmaceutical manufacturing. Clear legal pathways now exist in Europe.